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Abstract 
Background: Plasmodium falciparum prevalence (PfPR) is a widely used metric for assessing malaria transmission 
intensity. This study was carried out concurrently with the RTS,S/AS01 candidate malaria vaccine Phase III trial and 
estimated PfPR over ≤ 4 standardized cross‑sectional surveys.
Methods: This epidemiology study (NCT01190202) was conducted in 8 sites from 6 countries (Burkina Faso, Gabon, 
Ghana, Kenya, Malawi, and Tanzania), between March 2011 and December 2013. Participants were enrolled in a 2:1:1 
ratio according to age category: 6 months–4 years, 5–19 years, and ≥ 20 years, respectively, per year and per centre. 
All sites carried out surveys 1–3 while survey 4 was conducted only in 3 sites. Surveys were usually performed during 
the peak malaria parasite transmission season, in one home visit, when medical history and malaria risk factors/pre‑
vention measures were collected, and a blood sample taken for rapid diagnostic test, microscopy, and haemoglobin 
measurement. PfPR was estimated by site and age category.
Results: Overall, 6401 (survey 1), 6411 (survey 2), 6400 (survey 3), and 2399 (survey 4) individuals were included in 
the analyses. In the 6 months–4 years age group, the lowest prevalence (assessed using microscopy) was observed 
in 2 Tanzanian centres (4.6% for Korogwe and 9.95% for Bagamoyo) and Lambaréné, Gabon (6.0%), while the highest 
PfPR was recorded for Nanoro, Burkina Faso (52.5%). PfPR significantly decreased over the 3 years in Agogo (Ghana), 
Kombewa (Kenya), Lilongwe (Malawi), and Bagamoyo (Tanzania), and a trend for increased PfPR was observed over 
the 4 surveys for Kintampo, Ghana. Over the 4 surveys, for all sites, PfPR was predominantly higher in the 5–19 years 
group than in the other age categories. Occurrence of fever and anaemia was associated with high P. falciparum 
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Background
The burden of malaria remains the highest in sub-Saha-
ran Africa, with 90% of cases and 92% of malaria deaths 
occurring in this region alone in 2015 [1]. Reducing the 
burden relies, among other factors, on accurate estima-
tions of malaria transmission intensity (MTI), which 
determines the average age of first exposure, the rate of 
development of immunity, and consequently the age 
pattern of clinical disease [2, 3]. An effective and read-
ily available approach to evaluate MTI is by using the 
Plasmodium falciparum prevalence (PfPR), defined as 
the prevalence of asexual blood stage infection in human 
hosts. PfPR is a widely accepted and long-standing meas-
urement of the level of malaria risk in a community, with 
proven biological, epidemiological and statistical proper-
ties and consistent with the historical hypo-, meso- and 
hyper-endemic malaria categorizations [4, 5]. PfPR may 
vary seasonally, due to variable ecological conditions, and 
is influenced by the population immunity against malaria 
[6].
Between 2000 and 2015, malaria transmission in 
Africa, as assessed by PfPR, has decreased to almost half 
and this was correlated with a 40% decrease in the inci-
dence of clinical disease [7]. This was due to significant 
and consistent investment in campaigns to increase the 
coverage of malaria control interventions, among which 
the use of insecticide-treated nets (ITNs) was assessed as 
the most effective, followed by artemisinin-based combi-
nation therapy and indoor residual spraying (IRS) [7].
This study was designed to evaluate estimates of PfPR 
using microscopy, over a period of 3 years in sites from 
several sub-Saharan African countries, concurrently with 
and in the same environs as (but independently from) a 
Phase III clinical trial of the GSK’s candidate malaria vac-
cine RTS,S/AS01 [8–11]. Associations between malaria 
infection and occurrence of fever and anaemia, use of 
malaria control measures, or presence of malaria risk fac-
tors were also assessed during the study. Standardized 
study procedures were used to facilitate comparisons 
between sites and to provide robust data for subsequent 
upload to global databases such as the Malaria Atlas Pro-
ject [12]. Study methodologies closely followed those of 
the Malaria Indicator Survey [13].
Methods
Study design and survey population
This multicentre, epidemiology study was conducted 
between March 2011 and December 2013, and com-
prised up to 4 cross-sectional surveys. Among the 11 
sites (distributed in 7 countries) which implemented the 
phase III trial of the candidate malaria vaccine RTS,S/
AS01, 8 centres in Burkina Faso, Gabon, Ghana, Kenya, 
Malawi, and Tanzania agreed to participate and were 
included in this study. Five centres conducted 3 surveys 
and 3 centres (Nanoro in Burkina Faso, Lambaréné in 
Gabon, and Kintampo in Ghana) conducted 4 surveys, 
with the first 2 surveys carried out between March 2011 
and January 2012 (Fig. 1). All surveys were conducted at 
the peak of malaria transmission (i.e. the end of rainy sea-
son) [8], except for the first surveys in the 3 centres that 
conducted 4 surveys.
Eligible participants were  ≥  6  months of age and not 
actively participating in either malaria vaccine or anti-malar-
ial drug trials. Selection of study participants was based on 
either an existing demographic surveillance system, if avail-
able, or enumeration lists of all households in the study area. 
Children < 5 years (for the former) or households (for the 
latter) were randomly selected according to a computer-gen-
erated list. For each selected child ≥ 6 months to < 5 years 
old (6 months–4 years), another participant from the same 
household was considered for enrolment: either an indi-
vidual 5–19 years old (5–19 years) or aged 20 years or more 
(≥ 20 years). To allow for a 10% non-response rate, 440 chil-
dren 6 months–4 years were selected from the demographic 
surveillance system or, when unavailable, 660 houses 
were selected from enumeration lists, assuming 65–70% 
of houses will have children 6  months–4  years of age. To 
minimize sampling bias, 3 attempts were made to establish 
contact with a household before replacing it. If more than 1 
child aged 6 months–4 years lived in the house, 1 was ran-
domly selected.
Ethical considerations
The trial protocol was approved by the ethical review 
board and national regulatory authorities at each study 
site and partner institutions. The survey was undertaken 
in accordance with the Good Clinical Practice Guidelines 
parasitaemia. Univariate analyses showed a significant association of anti‑malarial treatment in 4 surveys (odds ratios 
[ORs]: 0.52, 0.52, 0.68, 0.41) and bed net use in 2 surveys (ORs: 0.63, 0.68, 1.03, 1.78) with lower risk of malaria infection.
Conclusion: Local PfPR differed substantially between sites and age groups. In children 6 months–4 years old, a 
significant decrease in prevalence over the 3 years was observed in 4 out of the 8 study sites.
Trial registration Clinical Trials.gov identifier: NCT01190202:NCT. GSK Study ID numbers: 114001
Keywords: Epidemiology, Malaria, Transmission, Prevalence, Plasmodium falciparum, Anaemia
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[14]. Depending on the age of the participants and local 
requirements, written informed consent and informed 
assent (where applicable) were obtained. Illiterate parents 
or legal representatives signed the consent form with a 
thumbprint, and a literate witness countersigned it. The 
study is registered at ClinicalTrials.gov (NCT01190202) 
and a summary of the protocol is available at http://www.
gsk-clinicalstudyregister.com (ID: 114001).
Data collection
Demographic information, medical history, socio-eco-
nomic factors, and environmental and ecological fac-
tors were collected at each survey, during home visits. A 
blood sample was collected by finger prick for rapid diag-
nostic test, thin and thick blood film, haemoglobin meas-
urement, and filter paper blood spot. Blood smears were 
examined by two independent microscopists, and dis-
crepancies were settled by a third reader. Parasite density 
was estimated by examination of 100 high powered fields, 
either against measured blood volume [15] or against 
blood cell concentration [16] or by counting parasites 
against 200 white blood cells and assuming 8000 white 
blood cells/µl. Haemoglobin concentration was assessed 
using a spectrophotometer (Hemocue). Anaemia was 
managed according to national guidelines [17].
Endpoints
Parasite density (parasites/μl) was defined as the geo-
metric mean of 2 blood smear-reading values if the 
participant status was defined as positive. The parasite 
densities were grouped into the following predefined 
classes: low (<  2500 parasites/μl); medium (2500–9999 
parasites/µl), high (10,000–19,999 parasites/μl), and 
very high (≥  20,000 parasites/μl). Fever was defined as 
an axillary temperature ≥  37.5  °C, or a history of fever 
reported in the 24 h prior to each survey. Anaemia was 
considered as non-severe for haemoglobin when between 
7  g/dl and  <  11–13  g/dl, depending on the age group 
(6 months–5, 5–11, 12–13, and > 13 years), gender and 
pregnancy status, and severe for a haemoglobin cut-off 
of  <  7  g/dl, regardless of age and gender [18, 19]. Sero-
conversion rates, which were derived from age specific 
anti-malaria antibody prevalence [20], were also meas-
ured in the study and will be presented elsewhere.
Statistical analysis
The sample size was computed for each centre sepa-
rately and used to estimate point prevalence of infection 
among children in the 6  months–4  years group during 
one cross-sectional survey. The effective sample size was 
computed to obtain an estimation of the prevalence of 
infection with a relative standard error ≤ 0.25. To meet 
this criterion of precision, the effective sample size was 
estimated at 400 eligible participants per study centre. 
For participants in the 5–19 years or ≥ 20 years groups, a 
relative standard error ≤ 0.35 was considered acceptable, 
as the sample size of 200 eligible participants in both age 
categories per centre was assumed to be sufficient.
Analyses were carried out on data from all evaluable 
participants, i.e. those meeting all eligibility criteria, 
complying with protocol procedures and with available 
laboratory blood sample for PfPR and serology data.
Fig. 1 Flow diagram. N number of participants
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Demographics and survey data
Descriptive analyses were conducted for demographic 
and medical history characteristics, socio-economic fac-
tors and environmental and ecological factors. For each 
centre, unadjusted odds ratios (OR) with 95% confidence 
intervals (CIs) were computed for the association of 
malaria control measure or risk factor with the risk of P. 
falciparum infection.
Parasite prevalence and anaemia status
The analysis of PfPR was conducted by year, site, age 
group and year of age for children younger than 5 years. 
Pooled prevalence across centres was done by age class 
using generalized estimating equations in order to take 
into account the correlation between participants from 
each site/country [21, 22], and heterogeneity among 
centers was tested using Cochran’s Q test based upon 
inverse variance weights.
Univariate analysis using logistic regression was con-
ducted to determine the association between infection 
and anaemia, malaria control measures, or malaria risk 
factors. ORs (equal to the hazard ratio of the logistic 
regression) were estimated in the entire population for 
each centre separately and also adjusted with the centre 
as a random effect.
Statistical analyses were performed using SAS version 9.2.
Results
Study population
The number of participants enrolled and reasons for 
exclusion from analyses are presented in Fig.  1. Demo-
graphic and socio-economic characteristics of partici-
pants, as well as the use of malaria prevention measures 
are summarized in Table 1 for the 6 months–5 years age 
category. The number of enrolled participants and male 
to female ratio was similar between sites and over the 
3  years. As study centres were classified as rural, semi-
rural or urban, access to electricity, or source of drink-
ing water varied substantially between centres (Table 1). 
Similarly, reported malaria treatment and use of preven-
tive measures varied between centres, but were compa-
rable for the same centre over the years (Table  1). The 
proportion of participants sleeping under a bed net the 
night prior to each survey varied greatly over the 3 years 
and across all age groups. For the 6  months–4  years 
age category, the lowest reported use of bed nets was 
reported in Nanoro (33.3%) and Kintampo (39.4%) for 
the first survey, but at survey 4 it increased up to 94.0 
and 80.8% respectively (Table 1). Exposure to IRS in the 
12  months prior to each survey was reported for a low 
proportion of participants; the highest proportion was 
documented in Agogo, and varied between 3.5% (survey 
2) and 11.1% (survey 1) for households of children aged 
6 months–4 years (Table 1).
Additional file 1: Tables S1 and S2 summarize the data 
for the 5–19 and ≥ 20 years age groups.
Plasmodium falciparum prevalence (PfPR)
Within each age group, PfPR varied substantially between 
centres. No consistent patterns of change over the 3 years 
could be identified across age groups (Table 2).
In the 6  months–4  years age group, the estimated 
pooled PfPR varied in time between 17.9% and 28.9%. 
In the 5–19  years age group, pooled PfPRs across the 
3  years were in the 28.2–45.6% range, while in par-
ticipants ≥ 20 years of age, pooled PfPR varied over the 
3 years between 9.2% and 15.4% (Table 2). Heterogeneity 
across centres for PfPR was significant in each age cate-
gory (Cochran’s Q test p < 0.0001).
In the 6  months–4  years age category, at survey 1, 
the lowest prevalence was observed in the 2 Tanza-
nian centres (4.6% for Korogwe and 10.0% for Baga-
moyo) and Lambaréné, Gabon (6.0%). The highest PfPR 
was recorded in Nanoro (52.5%). In this age group and 
at the time of survey 3, the infection prevalence signifi-
cantly decreased in Agogo (Ghana), Kombewa (Kenya), 
Lilongwe (Malawi), and Bagamoyo (Tanzania), as shown 
by non-overlapping 95% CI. A trend for decreased PfPR 
was observed over the last 3 surveys for Nanoro, while 
in Kintampo, PfPR tended to increase over the last 3 sur-
veys (Table 2, Fig. 2). Within the 6 months–4 years cat-
egory, PfPR increased with age (Fig. 3).
Across all centres and years, PfPRs were higher in the 
5–19 years age group compared to the 6 months–4 years 
group. The lowest PfPRs in individuals aged 5–19  years 
were recorded at the 2 Tanzanian sites, for which a signifi-
cant decrease was documented from survey 1 to survey 2. 
The highest values were observed for Nanoro, with a PfPR 
of 59.1% at survey 1 and 70.7% at survey 4, but showing a 
decrease if only the last 3 surveys were considered, with 
a peak at survey 2 (PfPR = 81.8%). PfPR was also high in 
Kombewa, varying from 42.0% (survey 2) to 54.2% (survey 
3) over the 3 surveys conducted. A trend for increasing 
PfPR was observed for Kintampo, while PfPR decreased in 
Lilongwe over the study period (Table 2).
Plasmodium falciparum prevalence was significantly 
lower and varied less by site in adults aged  ≥  20  years 
compared with the other age categories. In Nanoro, a 
significant increase in prevalence was observed from 
the time of survey 1 (14.9%) to surveys 2 (32.0%) and 3 
(42.7%), but PfPR decreased again to 25.5% at the time 
the fourth survey was conducted. High prevalence in 
adults was also observed in Kintampo, and was relatively 
stable over the years (between 11.1 and 17.7%), while a 
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trend for decreasing PfPR was observed for Bagamoyo 
(Table 2).
Similar percentages of P. falciparum-infected individu-
als were also observed by rapid diagnostic test (Addi-
tional file 2: Table S1).
Infection by Plasmodium malariae, Plasmodium vivax 
and Plasmodium ovale was rarely observed in all sites 
across all surveys, in less than 5% of the participants 
(Additional file 2: Table S2).
Occurrence of fever and anaemia
The percentage of participants of all ages reporting 
fever in the 24  h prior to each survey was significantly 
higher in P. falciparum-infected than in non-infected 
Fig. 2 Decrease of Plasmodium falciparum prevalence over the study period, by site and age group. M month, Y year
Fig. 3 Plasmodium falciparum prevalence by age, in the 6 months–4 years category, by site and study year. M month, Y year
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individuals: 26.0% (95% CI 23.7–28.5) versus 13.1% (95% 
CI 12.2–14.0) for survey 1, 17.7% (95% CI 15.6–20.0) ver-
sus 12.3% (95% CI 11.4–13.2) for survey 2, 23.8% (95% CI 
21.5–26.2) versus 12.1% (95% CI 11.2–13.0) for survey 3, 
and 21.5% (95% CI 18.6–24.7) versus 9.6% (95% CI 8.3–
11.1) for survey 4. The same trend was observed in each 
age group (Fig. 4a; Additional file 1: Figure S1). The pro-
portion of participants with reported fever varied greatly 
between centres for all age groups.
In the 6 months–4 years age group, occurrence of fever 
(measured or reported with the last 24  h) tended to be 
higher in children with higher parasite density, although 
this differed by site (Fig.  4a). Prevalence of fever was 
lower in Nanoro when compared with other sites with 
high PfPR, for each of the 4 surveys. Occurrence of fever 
in the other age groups also increased with increasing 
parasite density, although this trend varied greatly across 
centres (Additional file 1: Figure S1).
Anaemia occurred more frequently in P. falciparum-
infected compared to non-infected individuals (Fig.  4b; 
Additional file  1: Figure S2); prevalence of anaemia did 
not appear to be related to PfPR. Severe anaemia [19] 
was reported in 5.4–9.6, 0.8–2.4 and 0.0–1.4% of infected 
participants in each of the 3 age groups, respectively.
Plasmodium falciparum infection was a significant 
risk factor for anaemia (p  <  0.001), with estimated cen-
tre adjusted ORs of 1.89 (95% CI 1.47–2.35) for survey 1, 
1.64 (95% CI 1.40–1.90) for survey 2, 1.61 (95% CI 1.19–
2.19) for survey 3, and 1.76 (95% CI 1.40–2.19) for sur-
vey 4. ORs varied by site and study survey. For survey 3, 
infection was not associated with anaemia in Bagamoyo, 
Tanzania (OR  =  0.30; 95% CI 0.08–1.17). For all other 
sites and surveys, OR values ranged between 1.21 (95% 
CI 0.89–1.65) and 4.08 (95% CI 0.88–18.98) (Additional 
file 3: Table S1).
Malaria control measures and risk factors for malaria 
infection
Reported use of preventive measures varied substantially 
across study centres (Table 1; Additional file 3: Table S2). 
Having slept under a bed net the night before the survey 
visit was significantly associated with lower odds of infec-
tion in the first 2 surveys, with OR = 0.63 (95% CI 0.56–
0.71) for survey 1 and 0.68 (95% CI 0.60–0.78) for survey 
2, but not for the last 2 surveys (OR  =  1.03 [95% CI 
0.89–1.20] for survey 3 and 17.8 [95% CI 1.44–2.20] for 
survey 4) (Table 3). Risk of malaria infection was lower in 
participants who reported having received an anti-malar-
ial treatment in the previous 14 days; OR values ranged 
between 0.41 and 0.68 across the 3 years. Household IRS 
in the 12 months prior to the survey was only evaluated 
in centres where exposure to IRS was reported, but over-
all, it was associated with decreased odds of infection by 
P. falciparum (Table 3). Reported personal use of insecti-
cide sprays was also associated with lower odds of infec-
tion over the years, with ORs varying between 0.39 and 
0.57 (Table 3).
Discussion
This study showed that, among regions where the RTS,S/
AS01 Phase III clinical trial was implemented, PfPR dif-
fered greatly by age and site; nevertheless, a higher 
malaria prevalence in the 5–19  years age group was 
observed consistently in all sites. Burkina Faso was the 
country with the highest PfPRs over the 3  years, while 
the lowest prevalence was consistently observed in the 
2 Tanzanian sites and Lambaréné in Gabon. In children 
aged 6 months–4 years, the age group for which the high-
est morbidity and mortality due to malaria is observed 
[23], a significant decrease in PfPR was observed over 
time at 3 sites: Kombewa (Kenya), Lilongwe (Malawi) and 
Bagamayo (Tanzania). The use of anti-malarial treatment 
was associated with reduced odds of P. falciparum infec-
tion for all sites.
The higher PfPR observed in Burkina Faso is not sur-
prising and is in line with previous reports [24]. In 
Nouna, Burkina Faso, malaria prevalence in children 
under 5 was 57.7% [24], similar to that observed in 
Nanoro in our study. The results also confirm a lower 
PfPR in the younger 6  months–5  years age group com-
pared with children over 5  years of age reported in 
Nouna [24]. A decline of PfPR over time was observed 
when the surveys at the same 3 time points were con-
sidered, in line with reports of a consistently decreased 
prevalence between 2009 and 2011, compared to 2000 
[25]. A high prevalence was also observed in Kombewa, 
Kenya, for which data for the last 2 surveys seems to be 
in line with previous reports in a similar timeframe and 
geographical setting for children 0–5 years [26], although 
larger values were observed in our study for the other age 
groups. Among the sites in Ghana, lower PfPR values in 
Agogo than in Kintampo were consistently documented 
(See figure on next page.) 
Fig. 4 Prevalence of fever (a), anaemia and severe anaemia and haemoglobin concentration (b) for the 6 months–4 years age category, by 
parasite‑density category and site. M month, Y year. Prevalence was calculated as the percentage of children with reported fever/anaemia/severe 
anaemia in each parasite‑density category. The sites are ordered according to increasing values of Plasmodium falciparum prevalence in the first 
survey
Page 10 of 15Drakeley et al. Malar J  (2017) 16:433 
Page 11 of 15Drakeley et al. Malar J  (2017) 16:433 
in our study. This difference is not surprising, as marked 
heterogeneity of P. falciparum infection was previously 
reported [27].
The lower P. falciparum prevalence noted in the Tan-
zanian centres is in agreement with recent estimations of 
PfPR by rapid diagnostic test in a community survey [28], 
and reports of a decline in malaria incidence in this coun-
try, following scale up of malaria control interventions 
[29]. Lilongwe, Malawi was the only other site where a 
consistent decrease over time was observed in, both for 
the 6  months–5  years and the 5–19  years age groups. 
The estimated PfPRs compared fairly well with the P. fal-
ciparum infection prevalence detected microscopically 
from a study conducted in southern Malawi from 2012 
to 2014, although larger values were reported in the same 
study when real-time polymerase chain reaction (PCR) 
was used for parasite detection [30]. In Lambaréné, the 
estimated PfPR was lower in the 6  months–5  years age 
group than in the 5–19  years one, which is consistent 
with previous observation of an increase in age of the 
malaria high-risk population in Gabon between 2008 and 
2011 [31].
Ultimately, the PfPRs’ heterogeneity across the 8 study 
sites represents well the variability of transmission inten-
sity in sub-Saharan Africa [32, 33], and confirms that 
RTS,S/AS01 vaccine efficacy was evaluated at varying 
levels of MTI [34].
Differences across centres were also observed in rela-
tion to the use of anti-malarials and control measures, 
but they are also likely to be associated with other extrin-
sic factors such as social, behavioural, economic and local 
policies. Previous anti-malarial treatment (in all surveys) 
and use of bed nets (in ≥ 2 surveys) was associated with 
a lower risk of infection for the majority of the sites. Dur-
ing the study, the proportion of participants having taken 
malaria treatment varied widely in centres with high 
malaria prevalence; the lowest recorded use of malaria 
treatment was in Nanoro, Burkina Faso (0.5–2.5% of 
participants) and the highest in Kintampo, Ghana (up 
to 21.9% of participants). Of note, to our knowledge, 
Seasonal Malaria Chemoprevention measures as recom-
mended by the World Health Organization had not been 
implemented at the time the study ended in any of the 
study sites [35]. This finding may be explained by a num-
ber of highly interrelated extrinsic environmental, social, 
and economic factors such as diagnosis confirmation and 
local treatment practices, care seeking behaviour, access 
to health facilities and availability of local anti-malarials 
[36]. The discrepancy between infection prevalence and 
infrequent use of anti-malarials at some sites may be 
related to the immunity afforded by chronic infections 
resulting in asymptomatic parasite carriage, which have 
been widely described in P. falciparum endemic areas, 
including Africa [37].
Bed net use (on the night before the survey) was high in 
all sites throughout the 4 years and was associated with 
reduced risk of infection. Although recent data confirm 
the effectiveness of ITNs [7], reports in the literature 
from the period covered by our study did not always evi-
dence an association between bed net use and lower odds 
of infection at all sites. For instance, while a national dis-
tribution campaign in Burkina Faso led to an increase in 
the use of ITNs, the more frequent use of bed nets was 
not associated with a decline in parasitaemia in children 
under 5  years of age [38], as was the case in The Gam-
bia [27]. In Malawi, use of ITN following a high coverage 
of malaria interventions was associated with protection 
against infection, but P. falciparum prevalence remained 
high, especially in school-aged children [30].
Increased use of ITNs and IRS has already been asso-
ciated with a reduction in malaria burden through a 
population effect, and the fact that the results of these 
measures have varied across regions [39–47] and by age 
group [30] is mainly due to issues in their implementa-
tion, although differences in the dominant malaria vector 
species could also play a role [48]. Of note, in this study, 
Table 3 Odds ratios analysis of  P. falciparum infection in relation to reported usage of antimalarial treatment and pre-
vention measures
IRS indoor residual spray
a To spray interior walls
Odds ratio (95% confidence interval)
Survey 1 Survey 2 Survey 3 Survey 4
Malaria treatment in past 14 days (yes vs. no) 0.52 (0.0–0.68) 0.52 (0.38–0.69) 0.68 (0.52–0.89) 0.41 (0.24–0.70)
Slept under bed net night before (yes vs. no) 0.63 (0.56–0.71) 0.68 (0.60–0.78) 1.03 (0.89–1.20) 1.78 (1.44–2.20)
Use of at least one of the following over 7 days: mosquito coils—insecticide 
spray—commercial or traditional repellents
0.44 (0.36–0.54) 0.60 (0.49–0.74) 0.54 (0.44–0.67) 0.25 (0.19–0.33)
IRS in past 12  monthsa (yes vs. no) 0.58 (0.33–0.99) 0.31 (0.07–1.31) 0.80 (0.18–3.65) 1.18 (0.22–6.45)
Insecticide spray use in past 7 days (yes vs. no) 0.39 (0.24–0.64) 0.43 (0.23–0.80) 0.57 (0.31–1.04) 0.49 (0.17–0.90)
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information on using malaria medication or control 
measures was based on questions such as sleeping under 
a bed net the night before the survey, taking anti-malar-
ial medication during the past 14  days, or exposure to 
IRS during the past 12 months, which may induce recall 
biases or generalize usage of bed net based on the report 
for 1 night. Moreover, malaria control interventions may 
be targeted to areas with higher parasite prevalence and 
this, together with variations in coverage within an area, 
may confound any observations.
As expected, both anaemia and fever were associated 
with P. falciparum-infection in this study. OR analyses 
confirmed P. falciparum infection to be a significant risk 
factor for anaemia, with ORs ranging from 1.21 to 4.08 
across all sites and surveys (notwithstanding the negative 
association found in Bagamoyo at survey 3), consistent 
with results from other studies [49–51].
Overall, fever was associated with high parasite densi-
ties (≥  10,000 parasites/μl). There was a trend towards a 
higher association between fever and parasite density in 
the youngest age group, but results varied widely across 
centres. The lower fever prevalence observed in Nanoro, 
the site with the highest overall PfPR for all surveys and 
age groups, seems to be in line with previous findings in 
Burkina Faso, with 85–90% of parasite-positive individuals 
showing no fever [25]. However, in sites with consistently 
low PfPR for the 6  months–4  years age group (Lam-
baréné, Lilongwe, Korogwe, Kintampo), fever prevalence 
was also substantial for low to medium parasite densities 
(<  10,000 parasites/μl). These results show that a lower 
parasite density was associated with fever at sites where 
PfPR (and therefore MTI) was lower, as children in regions 
with moderate-to-high levels of MTI may develop partial 
immunity to malaria more easily and at an early age, mani-
fested through a decrease in symptoms [37, 52]. Of note, 
a larger prevalence of fever, regardless of recorded para-
sitaemia, was observed in Kintampo compared with the 
other study sites; moreover, in the 6 months–4 years age 
group, fever was reported for 31.0–50.2% of non-infected 
children. However, this observation is in agreement with 
reports of a high incidence of non-malaria fever in chil-
dren born between 2008 and 2011 in the area [53].
A number of key factors contributed to the quality and 
reliability of results presented in this paper. Standard meth-
odologies were used across centres to ensure comparability 
of results and to make certain that sampling was representa-
tive across catchment areas which participated in the Phase 
III trial. This allowed for a surplus in the number of ran-
domly selected households in order to take into account 
non-response and to minimize sampling bias. However, the 
sampling followed a non-probability method, as the targeted 
population represented a convenience sample, and therefore, 
generalization of the results should be made with caution.
The study has several limitations. Four surveys were 
conducted only in 3 study sites, as the study ended in 
December 2013, along with the Phase III trial, and at that 
time, 5 centres had not conducted the fourth survey. For 
some centres, the first survey was carried out outside 
the peak transmission season. P. falciparum prevalence 
was assessed microscopically, a method which underes-
timates the true level of infection when compared with 
molecular (PCR) detection [28, 54]. The cut-offs used to 
define anaemia and severe anaemia were based on the 
haemoglobin levels at sea level as recommended by the 
World Health Organization, but were not adjusted for 
each site, and this could have impacted the estimation of 
anaemia prevalence.
Malaria control intervention may have a different effect 
and/or impact on malaria morbidity at different levels of 
MTI. Therefore, the assessment of MTI in parallel to effi-
cacy trials for new malaria control interventions is essen-
tial for the generalization of trial results to other settings 
and to guide their implementation [55–58]. When 
administered as a 4-dose schedule at months 0, 1, 2 and 
20, the vaccine efficacy of RTS,S/AS01 against clinical 
malaria estimated in the Phase III trial was 39.0% (95% CI 
34.3–43.3), over a median follow-up period of 48 months 
since first vaccination of children 5–17 months old [59], 
up to the year 2014. However, vaccine efficacy varied 
greatly among study sites, although there was no evi-
dence for a statistically significant interaction with MTI 
[10]. Of note, ordering the sites by increasing PfPR for 
the 4 study years provided a similar ranking as when 
using incidence of clinical malaria, measured in control 
infants 6–12 weeks of age at enrollment in the Phase III 
study during 12 months of follow-up [10, 11], especially 
for the 6 months–4 years and 5–19 years age categories. 
For all 4 years in our study, the site with the highest PfPR 
was Nanoro, for which the highest malaria incidence was 
observed in the Phase III trial, while the lowest values 
were documented for Korogwe in both studies. The order 
of the other sites also compared fairly between PfPR and 
clinical incidence of malaria, suggesting that the control 
group could serve as a surrogate for relative malaria para-
site transmission intensity. The data in our study contrib-
ute to an improved interpretation of site variations in the 
Phase III vaccine efficacy study of RTS,S/AS01.
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